Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy
Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy
Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block FcγRIIB and provided in vivo proof-of-concept for their ability to overcome FcγRIIB-mediated resistance.
Journal Article
e1069939
Roghanian, Ali
e2b032c2-60a0-4522-a3d8-56a768792f36
Cragg, Mark S
ec97f80e-f3c8-49b7-a960-20dff648b78c
Frendéus, Björn
c960f7ce-006a-4ea9-8aac-f6f0304a746c
February 2016
Roghanian, Ali
e2b032c2-60a0-4522-a3d8-56a768792f36
Cragg, Mark S
ec97f80e-f3c8-49b7-a960-20dff648b78c
Frendéus, Björn
c960f7ce-006a-4ea9-8aac-f6f0304a746c
Roghanian, Ali, Cragg, Mark S and Frendéus, Björn
(2016)
Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy.
OncoImmunology, 5 (2), .
(doi:10.1080/2162402X.2015.1069939).
Abstract
Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block FcγRIIB and provided in vivo proof-of-concept for their ability to overcome FcγRIIB-mediated resistance.
This record has no associated files available for download.
More information
Published date: February 2016
Keywords:
Journal Article
Identifiers
Local EPrints ID: 413678
URI: http://eprints.soton.ac.uk/id/eprint/413678
ISSN: 2162-4011
PURE UUID: de37fa51-d81a-4dcf-b5c2-a9ef58336509
Catalogue record
Date deposited: 31 Aug 2017 16:31
Last modified: 16 Mar 2024 04:01
Export record
Altmetrics
Contributors
Author:
Björn Frendéus
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics